about
Is It worth Considering Circulating microRNAs in Multiple Sclerosis?Animal Models for Progressive Multifocal LeukoencephalopathyImmune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk FactorsUse of natalizumab in multiple sclerosis: current perspectives.A link between long-term natalizumab dosing in MS and PML: Putting the puzzle togetherImmunological Markers for PML Prediction in MS Patients Treated with NatalizumabSeeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.A box of chocolatesNatalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.PML risk stratification using anti-JCV antibody index and L-selectin.[MiRNAs: new actors in the physiopathology of multiple sclerosis].miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients.EGFL7 reduces CNS inflammation in mouse.Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.Dysregulated MicroRNA Involvement in Multiple Sclerosis by Induction of T Helper 17 Cell Differentiation.Involvement of miR-126 in autoimmune disorders.
P2860
Q26752505-837CC281-F282-4804-8672-7AE6AE2F9F27Q26853218-64B60DB8-638A-43C9-A7E1-2B039F2DC885Q28085415-67ABAA3C-084C-41B6-86ED-16CA7B9851C0Q31114633-9FD9B765-DF10-41F8-8322-B134EABEDA01Q33363188-A83E7385-63E6-4CD9-A05A-7572D8D7BF07Q34818048-3AFAC89E-F495-4931-A7CD-6AB6346B1683Q35625089-0255B4D7-25CC-4873-8DDA-F42B5C5FDA3BQ36767522-AF90A182-3646-4AFD-980C-14B1594589CAQ42158685-BD17CD7F-3A50-43AC-900C-4CB2F151E12AQ42181572-EC987378-245C-42AA-B37D-E363B0214A85Q48938768-F372820C-B640-4891-A59B-0F6361AE3752Q49485817-023D0400-8925-4E75-AB19-619AA2C7BD87Q51381933-1A7CAED3-1CBA-40C1-BAF6-1E257153F394Q52684358-515E6767-BFF6-4582-8C7E-34DC4CECB2C8Q53383288-DB17E569-F285-47C5-88C9-CEE0D764B803Q55265126-172F3E99-48AE-4DB1-820E-5564FDCE3208Q55437699-5F2D8ADC-9E22-4AE7-B425-657D60848AA5
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
MiR-126: a novel route for natalizumab action?
@en
MiR-126: a novel route for natalizumab action?
@nl
type
label
MiR-126: a novel route for natalizumab action?
@en
MiR-126: a novel route for natalizumab action?
@nl
prefLabel
MiR-126: a novel route for natalizumab action?
@en
MiR-126: a novel route for natalizumab action?
@nl
P2093
P2860
P356
P1476
MiR-126: a novel route for natalizumab action?
@en
P2093
Claudia Sievers
Francine Hoffmann
Jens Kuhle
Maria Meira
Raija L P Lindberg
Tobias Derfuss
P2860
P304
P356
10.1177/1352458514524998
P577
2014-03-05T00:00:00Z